Irritable Bowel Disease
12
1
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
1 terminated out of 12 trials
85.7%
-0.8% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
Health-Related Quality of Life Among Patients With Inflammatory Bowel Disease
Pain in Pediatric Patients - Internet Interventions for Disorders of Gut-brain Interaction
(FODMAP) Diet on Improving Symptoms of Patients With Irritable Bowel Syndrome
Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome
Relaxation Exercise and Education in Patients With Irritable Bowel Syndrome
Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers
Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon
Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease
Study of Thyroid Status in Patients With IBD
Improving Quality of Care With a Digital Behavioral Program in IBD Patient Centered Medical Home
Effects of Fasting and Hydro Colon Therapy Plus Probiotics on GI Microbiota in Intolerances and Irritable Bowel Syndrome
Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome